{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:10:41Z","timestamp":1760335841057,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.annonc.2020.03.302","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T17:27:07Z","timestamp":1586280427000},"page":"958-959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced salivary gland carcinoma expressing androgen receptor and HER2: targeted therapies first?"],"prefix":"10.1016","volume":"31","author":[{"given":"E.","family":"Quaquarini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sottotetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Presti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.03.302_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.03.302_bib2","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1002\/cam4.2602","article-title":"Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling","volume":"8","author":"Gargano","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2020.03.302_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.03.302_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers9020017","article-title":"Androgen receptor signaling in salivary gland cancer","volume":"9","author":"Dalin","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.annonc.2020.03.302_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fonc.2019.00701","article-title":"First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma\u2014a retrospective study","volume":"9","author":"Viscuse","year":"2019","journal-title":"Front Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420363912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420363912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:57:08Z","timestamp":1760335028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420363912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":5,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0923753420363912"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.03.302","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced salivary gland carcinoma expressing androgen receptor and HER2: targeted therapies first?","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.03.302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}